-DOCSTART- -X- O
New -X- _ O
therapeutic -X- _ O
approaches -X- _ O
are -X- _ O
urgently -X- _ O
needed -X- _ O
for -X- _ O
serious -X- _ O
diseases -X- _ O
, -X- _ O
including -X- _ O
cancer -X- _ O
, -X- _ O
cardiovascular -X- _ O
diseases -X- _ O
, -X- _ O
viral -X- _ B-Patient
infections -X- _ I-Patient
, -X- _ O
and -X- _ O
others. -X- _ O
A -X- _ O
recent -X- _ O
direction -X- _ O
in -X- _ O
drug -X- _ O
development -X- _ O
is -X- _ O
the -X- _ O
utilization -X- _ O
of -X- _ O
nucleic -X- _ O
acidbased -X- _ O
therapeutic -X- _ O
molecules -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
antisense -X- _ O
oligonucleotides -X- _ O
, -X- _ O
ribozymes -X- _ O
, -X- _ O
short -X- _ O
interfering -X- _ O
RNA -X- _ O
( -X- _ O
siRNA -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
microRNA -X- _ B-Intervention
( -X- _ I-Intervention
miRNA -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
miRNAs -X- _ B-Intervention
are -X- _ O
endogenous -X- _ O
, -X- _ O
short -X- _ O
, -X- _ O
non-coding -X- _ O
RNA -X- _ O
molecules. -X- _ O
Some -X- _ O
viruses -X- _ O
encode -X- _ O
their -X- _ O
own -X- _ O
miRNAs -X- _ O
, -X- _ O
which -X- _ O
play -X- _ O
pivotal -X- _ O
roles -X- _ O
in -X- _ O
viral -X- _ O
replication -X- _ O
and -X- _ O
immune -X- _ O
evasion -X- _ O
strategies. -X- _ O
Conversely -X- _ O
, -X- _ O
viruses -X- _ O
that -X- _ O
do -X- _ O
not -X- _ O
encode -X- _ O
miRNAs -X- _ O
may -X- _ O
manipulate -X- _ O
host -X- _ O
cell -X- _ O
miRNAs -X- _ O
for -X- _ O
the -X- _ O
benefits -X- _ O
of -X- _ O
their -X- _ O
replication. -X- _ O
miRNAs -X- _ B-Outcome
have -X- _ I-Outcome
therefore -X- _ I-Outcome
become -X- _ I-Outcome
attractive -X- _ I-Outcome
tools -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
study -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
pathogenesis. -X- _ I-Outcome
Lately -X- _ O
, -X- _ O
novel -X- _ O
therapeutic -X- _ O
strategies -X- _ O
based -X- _ O
on -X- _ O
miRNA -X- _ O
technology -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
viral -X- _ B-Patient
diseases -X- _ I-Patient
have -X- _ O
been -X- _ O
progressing -X- _ O
rapidly. -X- _ O
Although -X- _ O
this -X- _ O
new -X- _ O
generation -X- _ O
of -X- _ O
molecular -X- _ O
therapy -X- _ O
is -X- _ O
promising -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
still -X- _ O
several -X- _ O
challenges -X- _ O
to -X- _ O
face -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
targeting -X- _ B-Outcome
delivery -X- _ I-Outcome
to -X- _ I-Outcome
specific -X- _ I-Outcome
tissues -X- _ I-Outcome
, -X- _ I-Outcome
avoiding -X- _ I-Outcome
off-target -X- _ I-Outcome
effects -X- _ I-Outcome
of -X- _ I-Outcome
miRNAs -X- _ I-Outcome
, -X- _ I-Outcome
reducing -X- _ I-Outcome
the -X- _ I-Outcome
toxicity -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
drugs -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
overcoming -X- _ I-Outcome
mutations -X- _ I-Outcome
and -X- _ I-Outcome
drug -X- _ I-Outcome
resistance. -X- _ I-Outcome
In -X- _ O
this -X- _ O
article -X- _ O
, -X- _ O
we -X- _ O
review -X- _ O
the -X- _ O
current -X- _ O
knowledge -X- _ O
of -X- _ O
the -X- _ O
role -X- _ O
and -X- _ O
therapeutic -X- _ O
potential -X- _ O
of -X- _ O
miRNAs -X- _ O
in -X- _ O
viral -X- _ O
diseases -X- _ O
, -X- _ O
and -X- _ O
discuss -X- _ O
the -X- _ O
limitations -X- _ O
of -X- _ O
these -X- _ O
therapies -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
strategies -X- _ O
to -X- _ O
overcome -X- _ O
them -X- _ O
to -X- _ O
provide -X- _ O
safe -X- _ O
and -X- _ O
effective -X- _ O
clinical -X- _ O
applications -X- _ O
of -X- _ O
these -X- _ O
new -X- _ O
therapeutics -X- _ O
. -X- _ O

